ArticleCurrent microbiology2014
Mannosylated LigANI produced in Pichia pastoris protects hamsters against leptospirosis.
Article in Current microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- Design, Development and Immunogenic Evaluation of a Novel Lipl32 Recombinant Protein of Local Pathogenic Leptospira Serovars.Archives of Razi Institute · 2025Article
- Challenges and Strategies for Developing Recombinant Vaccines against Leptospirosis: Role of Expression Platforms and Adjuvants in Achieving Protective Efficacy.Pathogens (Basel, Switzerland) · 2023Review
- LigA formulated in AS04 or Montanide ISA720VG induced superior immune response compared to alum, which correlated to protective efficacy in a hamster model of leptospirosis.Frontiers in immunology · 2022Article
- Designing Adjuvant Formulations to Promote Immunogenicity and Protective Efficacy ofFrontiers in cellular and infection microbiology · 2022Article
- Production of a Hepatitis E Vaccine Candidate Using the Pichia pastoris Expression System.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Article
- Expression ofMicroorganisms · 2020Article
- DNA nanovaccines prepared using LemA antigen protect Golden Syrian hamsters against Leptospira lethal infection.Memorias do Instituto Oswaldo Cruz · 2020Article
- Leptospiral Immunoglobulin-Like Domain Proteins: Roles in Virulence and Immunity.Frontiers in immunology · 2020Review
- Influence of carbon source on cell size and production of anti LDL (-) single-chain variable fragment by a recombinant Pichia pastoris strain.Molecular biology reports · 2019Article
- Reverse Vaccinology: An Approach for Identifying Leptospiral Vaccine Candidates.International journal of molecular sciences · 2017Review
- Immunoprotective properties of recombinant LigA and LigB in a hamster model of acute leptospirosis.PloS one · 2017Article
- A Universal Vaccine against Leptospirosis: Are We Going in the Right Direction?Frontiers in immunology · 2017Article
- Immune response in hamsters immunised with a recombinant fragment of LigA from Leptospira interrogans, associated with carrier molecules.Memorias do Instituto Oswaldo Cruz · 2016Article
- DNA prime-protein boost based vaccination with a conserved region of leptospiral immunoglobulin-like A and B proteins enhances protection against leptospirosis.Memorias do Instituto Oswaldo Cruz · 2015Article
- Xanthan gum as an adjuvant in a subunit vaccine preparation against leptospirosis.BioMed research international · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The C-terminal region of the Leptospiral immunoglobulin-like A protein (LigA) contains six carboxy-terminal Ig-like repeat domains (LigANI). Subunit vaccine preparations based on recombinant LigANI produced in Escherichia coli, are promising vaccine candidates, albeit with variable efficacy. In the present study, LigANI was expressed in the methylotrophic yeast Pichia pastoris using a 12 L bioreactor to produce mannosylated LigANI (mLigANI) for use in a vaccine preparation against leptospirosis. Hamsters immunized with a mLigANI vaccine preparation produced a significant IgG antibody response (P < 0.001) and were protected (83.3 %; P < 0.001) against lethal challenge with 36× LD50 of a virulent strain of L. interrogans serovar Copenhageni. A vaccine preparation based on demannosylated mLigANI (nmLigANI) elicited an immune response in hamsters, but did not afford protection. The production of mLigANI in bioreactor by P. pastoris yielded ~50 mg L(-1) of recombinant protein. P. pastoris is a potential platform for the production of leptospiral antigens on an industrial scale. The results demonstrate that LigANI secreted by P. pastoris on mannosylated form (mLigANI) protect hamsters as subunit vaccine of L. interrogans lethal infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.